| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2004 | CA2075926C Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them |
| 04/06/2004 | CA2067381C Treatment of hiv infections and compounds useful therein |
| 04/06/2004 | CA2060616C Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers |
| 04/03/2004 | CA2453071A1 Genes and proteins for the production of polyene polyketides |
| 04/01/2004 | WO2004027381A2 Methods and compositions related to inhibiting nuclear envelope breakdown |
| 04/01/2004 | WO2004027061A1 Method of screening remedy for proliferative disease |
| 04/01/2004 | WO2004027049A2 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 04/01/2004 | WO2004027047A2 INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE AND USES THEREFOR |
| 04/01/2004 | WO2004027027A2 Method of inhibiting choroidal neovascularization |
| 04/01/2004 | WO2004027020A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 04/01/2004 | WO2004026930A2 The method for reducing inflammation using sti-571 or its salt |
| 04/01/2004 | WO2004026909A2 Method of treating rheumatoid arthritis by interfering with expression of dc-sign by macrophages and diagnosis thereof |
| 04/01/2004 | WO2004026881A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments |
| 04/01/2004 | WO2004026871A1 Novel pyrazolopyridine derivatves as pharmaceutical agents |
| 04/01/2004 | WO2004026865A1 Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026859A1 Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026851A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors |
| 04/01/2004 | WO2004026844A1 Methods and compositions of novel triazine compounds |
| 04/01/2004 | WO2004026842A1 Novel uracil derivatives and medicinal use thereof |
| 04/01/2004 | WO2004026841A1 Novel 6-substituted uracil derivative and therapeutic agent for allergic disease |
| 04/01/2004 | WO2004026834A1 Crystalline organic acid salt of amlodipine |
| 04/01/2004 | WO2004026833A1 Cyclic amine compound, process for producing the same, and use |
| 04/01/2004 | WO2004026832A1 Urea compound and use thereof |
| 04/01/2004 | WO2004026829A2 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors |
| 04/01/2004 | WO2004026827A1 Pyrrolidone derivatives as maob inhibitors |
| 04/01/2004 | WO2004026826A1 4-pyrrolidino-phenyl-benzyl ether derivatives |
| 04/01/2004 | WO2004026825A1 Pyrrolidone derivatives as maob inhibitors |
| 04/01/2004 | WO2004026818A1 New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| 04/01/2004 | WO2004026816A1 Aromatic liver x-receptor modulators |
| 04/01/2004 | WO2004026815A2 Phenol derivatives and their use as rotamase inhibitors |
| 04/01/2004 | WO2004026808A1 Manufacturing process for no-donating compounds such as no-donating diclofenac |
| 04/01/2004 | WO2004026406A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 04/01/2004 | WO2004026405A1 Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| 04/01/2004 | WO2004026361A1 Controllable drug releasing gradient coatings for medical devices |
| 04/01/2004 | WO2004026345A1 Control of nitric oxide bioactivity by perfluorocarbons |
| 04/01/2004 | WO2004026343A1 Site-specific gene conversion promoter and gene therapeutic |
| 04/01/2004 | WO2004026342A1 AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING |
| 04/01/2004 | WO2004026341A1 Immunotherapeutic for cancer |
| 04/01/2004 | WO2004026337A1 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug |
| 04/01/2004 | WO2004026335A1 Pharmaceutical composition comprising carriers for products |
| 04/01/2004 | WO2004026326A2 Antigen uptake receptor for candida albicans on dendritic cells |
| 04/01/2004 | WO2004026322A1 Method and preparation for preventing casualty caused by iodine radionuclides and optimising iodine metabolism in a postprophylaxis period |
| 04/01/2004 | WO2004026320A1 Vitreoretinal tamponades based on fluorosilicone fluids |
| 04/01/2004 | WO2004026319A2 Pharmaceutical compositions increasing camp useful for the treatment of cancers |
| 04/01/2004 | WO2004026318A1 HEPATITIS C VIRUS INHIBITOR COMPRISING α-GLYCOSYLCERAMIDE AS THE ACTIVE INGREDIENT |
| 04/01/2004 | WO2004026317A1 Histamine release inhibitor |
| 04/01/2004 | WO2004026316A1 Novel use of carbohydrates and compositions |
| 04/01/2004 | WO2004026314A1 Modified release formulations of oxcarbazepine and derivatives thereof |
| 04/01/2004 | WO2004026313A1 Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. |
| 04/01/2004 | WO2004026312A1 Use of a quinazoline derivative for treating lower urinary tract symptoms |
| 04/01/2004 | WO2004026311A2 Use of specific inhibitors of tyrosine kinases for immunomodulation |
| 04/01/2004 | WO2004026309A1 Effervescent formulations comprising apomorphine |
| 04/01/2004 | WO2004026308A1 Sustained release compound of acetamidophenol and tramadol |
| 04/01/2004 | WO2004026307A1 Triazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026306A2 Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| 04/01/2004 | WO2004026304A1 An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
| 04/01/2004 | WO2004026303A2 Use of posaconazole for the treatment of fungal infections |
| 04/01/2004 | WO2004026302A1 Methods of inhibiting tgf beta with substituted pyrazoles |
| 04/01/2004 | WO2004026301A1 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| 04/01/2004 | WO2004026300A1 COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS |
| 04/01/2004 | WO2004026299A1 Treatment of dyskinesia |
| 04/01/2004 | WO2004026297A1 Preparation for external use |
| 04/01/2004 | WO2004026296A1 Composition against stress-related diseases |
| 04/01/2004 | WO2004026295A2 Use of skin-protecting substances |
| 04/01/2004 | WO2004026294A1 Leucine-enriched nutritional compositions |
| 04/01/2004 | WO2004026293A2 Hemiasterlin derivatives for treating resistant tumors |
| 04/01/2004 | WO2004026292A1 Antitussives |
| 04/01/2004 | WO2004026291A1 Oral formulations of ibuprofen and tramadol, methods and preparation thereof |
| 04/01/2004 | WO2004026290A1 Method for treating depression and/or anxiety |
| 04/01/2004 | WO2004026289A1 Nutritional or therapeutic compositions |
| 04/01/2004 | WO2004026288A1 A treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells |
| 04/01/2004 | WO2004026287A1 Orally administrable composition for improving skin quality |
| 04/01/2004 | WO2004026286A2 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| 04/01/2004 | WO2004026285A2 Compositions and methods for treating heart disease |
| 04/01/2004 | WO2004026280A2 Granulate formulation of the rapamycin ester cci-779 |
| 04/01/2004 | WO2004026274A1 Skin photoageing and actinic damage treatment |
| 04/01/2004 | WO2004026267A2 Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them |
| 04/01/2004 | WO2004026262A2 Abuse-resistant pharmaceutical compositions |
| 04/01/2004 | WO2004026261A2 Composition containing ribavirin and use thereof |
| 04/01/2004 | WO2004026260A2 Prophylactic and therapeutic hiv aptamers |
| 04/01/2004 | WO2004026259A2 Transdermal compositions |
| 04/01/2004 | WO2004026258A2 Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease |
| 04/01/2004 | WO2004026257A2 Treatment of irritable bowel syndrome and related bowel diseases |
| 04/01/2004 | WO2004026256A2 Sustained-release opioid formulations and methods of use |
| 04/01/2004 | WO2004026255A2 Compositions and methods for preventing infection |
| 04/01/2004 | WO2004026253A2 Novel lapacho compounds and methods of use thereof |
| 04/01/2004 | WO2004026252A2 Glioma treatments |
| 04/01/2004 | WO2004026248A2 Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| 04/01/2004 | WO2004026247A2 Compositions and methods for separating amines and amino acids from their counter-enantiomers |
| 04/01/2004 | WO2004026246A2 Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
| 04/01/2004 | WO2004026243A2 Therapeutic uses of linear ketophosphonates |
| 04/01/2004 | WO2004026242A2 Substituted ketophosphonate inhibitors of tumor cell proliferation |
| 04/01/2004 | WO2004026241A2 Multistage formulation containing a biguanide and thiazolidindione derivatives |
| 04/01/2004 | WO2004026239A2 Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption |
| 04/01/2004 | WO2004026237A2 Compounds for the treatment of premature ejaculation |
| 04/01/2004 | WO2004026236A2 Cyclopentyl indole derivatives |
| 04/01/2004 | WO2004026235A2 Pharmaceutical compositions with improved dissolution |
| 04/01/2004 | WO2004026233A2 Mannitol formulation for integrin receptor antagonist |
| 04/01/2004 | WO2004026232A2 Vaginal health products |
| 04/01/2004 | WO2004026231A2 Formulation for lipophilic agents |